| Literature DB >> 29398487 |
Tomas Majtan1, Wendell Jones2, Jakub Krijt3, Insun Park4, Warren D Kruger5, Viktor Kožich3, Steven Bassnett2, Erez M Bublil6, Jan P Kraus7.
Abstract
Classical homocystinuria (HCU) is the most common inherited disorder of sulfur amino acid metabolism caused by deficiency in cystathionine beta-synthase (CBS) activity and characterized by severe elevation of homocysteine in blood and tissues. Treatment with dietary methionine restriction is not optimal, and poor compliance leads to serious complications. We developed an enzyme replacement therapy (ERT) and studied its efficacy in a severe form of HCU in mouse (the I278T model). Treatment was initiated before or after the onset of clinical symptoms in an effort to prevent or reverse the phenotype. ERT substantially reduced and sustained plasma homocysteine concentration at around 100 μM and normalized plasma cysteine for up to 9 months of treatment. Biochemical balance was also restored in the liver, kidney, and brain. Furthermore, ERT corrected liver glucose and lipid metabolism. The treatment prevented or reversed facial alopecia, fragile and lean phenotype, and low bone mass. In addition, structurally defective ciliary zonules in the eyes of I278T mice contained low density and/or broken fibers, while administration of ERT from birth partially rescued the ocular phenotype. In conclusion, ERT maintained an improved metabolic pattern and ameliorated many of the clinical complications in the I278T mouse model of HCU.Entities:
Keywords: PEGylation; alopecia; bone density; cystathionine beta-synthase; enzyme replacement; eye defect; homocysteine; inborn error of metabolism; metabolomics; preclinical studies
Mesh:
Substances:
Year: 2017 PMID: 29398487 PMCID: PMC5910661 DOI: 10.1016/j.ymthe.2017.12.014
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454